BR0312483A - Anticorpos e seus usos - Google Patents

Anticorpos e seus usos

Info

Publication number
BR0312483A
BR0312483A BR0312483-5A BR0312483A BR0312483A BR 0312483 A BR0312483 A BR 0312483A BR 0312483 A BR0312483 A BR 0312483A BR 0312483 A BR0312483 A BR 0312483A
Authority
BR
Brazil
Prior art keywords
antibodies
methods
metastasis
fragments
present
Prior art date
Application number
BR0312483-5A
Other languages
English (en)
Inventor
Avigdor Levanon
Raquel Ben-Levy
Daniel Plaksin
Yocheved Hagai
Hagit Hoch Mar-Chaim
Esther Szanthon
Original Assignee
Savient Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Savient Pharmaceuticals Inc filed Critical Savient Pharmaceuticals Inc
Publication of BR0312483A publication Critical patent/BR0312483A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • AIDS & HIV (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)

Abstract

"ANTICORPOS E SEUS USOS". A presente invenção provê anticorpos ou fragmentos dos mesmos que se ligam a células de câncer e são importantes em fenómenos fisiológicos tais como rolamento de células e metástase. Provê também métodos terapêuticos, métodos para diagnóstico, prognóstico e determinação do estágio da doença e composições usando os referidos anticorpos ou fragmentos dos mesmos. Os métodos e composições de acordo com a presente invenção podem ser usados no diagnóstico e na terapia de doenças como câncer, inclusive crescimento de tumor e metástase, leucemia, doença autoimune e doença inflamatória.
BR0312483-5A 2002-07-01 2003-06-30 Anticorpos e seus usos BR0312483A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18903202A 2002-07-01 2002-07-01
PCT/US2003/020602 WO2004003166A2 (en) 2002-07-01 2003-06-30 Antibodies and uses thereof

Publications (1)

Publication Number Publication Date
BR0312483A true BR0312483A (pt) 2005-08-09

Family

ID=29999594

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0312483-5A BR0312483A (pt) 2002-07-01 2003-06-30 Anticorpos e seus usos

Country Status (12)

Country Link
EP (1) EP1534332A4 (pt)
JP (1) JP2005536199A (pt)
KR (1) KR20060011925A (pt)
CN (1) CN1678347A (pt)
AU (1) AU2003263764A1 (pt)
BR (1) BR0312483A (pt)
CA (1) CA2491363A1 (pt)
IL (1) IL166063A0 (pt)
MX (1) MXPA05000272A (pt)
PL (1) PL374439A1 (pt)
RU (1) RU2005101621A (pt)
WO (1) WO2004003166A2 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20031714A1 (it) * 2003-09-05 2005-03-06 Gentium Spa Formazioni ad azione antitumorale.
CA2565872C (en) * 2004-05-11 2016-06-21 Abgenomics Corporation T-cell death-inducing epitopes
US20070298034A9 (en) * 2005-12-09 2007-12-27 Angela Widom Sulfotyrosine specific antibodies and uses therefor
DK2637672T3 (en) 2010-11-12 2018-10-22 Gentium S R L DEFIBROTID FOR USE IN PROPHYLAXY AND / OR TREATMENT OF GRAPHIC VERSUS HOST DISEASE (GVHD)
CA2838952C (en) 2011-06-13 2020-11-24 Stefan Bassarab Anti-psgl-1 antibodies and uses thereof
MX352085B (es) 2012-06-22 2017-11-08 Gentium S R L Método a base de euglobulina para determinar la actividad biológica de defibrótido.
EP3026122A1 (en) 2014-11-27 2016-06-01 Gentium S.p.A. Cellular-based method for determining the potency of defibrotide
KR101896751B1 (ko) * 2015-12-01 2018-10-04 주식회사 엘지화학 열가소성 수지, 이의 제조방법 및 이를 포함하는 열가소성 수지 조성물
MA53160A (fr) * 2018-07-20 2021-05-26 Pf Medicament Récepteur pour vista
CN111715409B (zh) * 2020-07-01 2021-07-23 中南大学 一种微细粒方铅矿的组合铅抑制剂及其应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1131084A4 (en) * 1998-10-30 2001-12-19 Genetics Inst INHIBITION OF DIFFERENTIATION OF CYTOTOXIC T CELLS BY P-SELECTINE LIGAND ANTAGONISTS (PSGL)
BR0109524A (pt) * 2000-03-24 2004-01-20 Genetics Inst Molécula de ácido nucleico isolada, vetor, célula hospedeira, método para produzir um polipeptìdeo, polipeptìdeo isolado, anticorpo, método para detectar a presença de um polipeptìdeo em uma amostra, kit, e, métodos para detectar a presença de uma molécula de ácido nucleico em uma amostra, para identificar um composto e para modular a atividade de um polipeptìdeo

Also Published As

Publication number Publication date
PL374439A1 (en) 2005-10-17
WO2004003166A2 (en) 2004-01-08
JP2005536199A (ja) 2005-12-02
WO2004003166A3 (en) 2005-03-10
EP1534332A4 (en) 2006-11-22
EP1534332A2 (en) 2005-06-01
CN1678347A (zh) 2005-10-05
AU2003263764A1 (en) 2004-01-19
RU2005101621A (ru) 2005-11-20
MXPA05000272A (es) 2005-09-20
KR20060011925A (ko) 2006-02-06
CA2491363A1 (en) 2004-01-08
IL166063A0 (en) 2006-01-15

Similar Documents

Publication Publication Date Title
Vieyra-Garcia et al. Benign T cells drive clinical skin inflammation in cutaneous T cell lymphoma
ATE353974T1 (de) Verfahren, zusammensetzungen und kits zur identifizierung und überwachung von brustkrebs
DE60226499D1 (de) Verwendung von antikörpern gegen das muc18-antigen
WO2006085984A3 (en) Immune cell biosensors and methods of using same
BR0110091A (pt) Composições e processos para terapia e diagnóstico de câncer de mama
WO2006076025A3 (en) Immune cell biosensors and methods of using same
ATE516047T1 (de) Ovr110-antikörperzusammensetzungen und anwendungsverfahren
BRPI0519775A2 (pt) proteÍna isolada de ligaÇço a antÍgeno, polinucleotÍdeo isolado, plasmÍdio e cÉlula isolada e composiÇço farmacÊutica
IL176007A0 (en) Antibodies specific to c35 and pharmaceutical compositions containing the same
DE60028830D1 (de) Anti-april antikörper und hybridomazellen
CY1113096T1 (el) Αντισωματα της ip-10 και οι χρησεις αυτων
DE69633121D1 (de) Tie-2 liganden, herstellungsverfahren und verwendung
WO2004053079A3 (en) Compositions, splice variants and methods relating to ovarian specific genes and proteins
IL145535A0 (en) Monoclonal antibodies, antigens and diagnosis and therapy of malignant diseases
DK0552296T3 (da) Monoklonale antistoffer fra mus
WO2005044990A3 (en) Use of differentially expressed nucleic acid sequences as biomarkers for cancer
BR0312483A (pt) Anticorpos e seus usos
BR0116764A (pt) moléculas isoladas compreendendo epitopos contendo porções sulfatadas, anticorpos para os referidos epitopos e seus usos
DE69841322D1 (de) Hepatitis c rezeptorprotein cd81
ATE514718T1 (de) Peptabody für krebsbehandlung
BRPI0411945A (pt) Anticorpos e seus usos
DK1051491T3 (da) Equin Fc Epsilon receptor-alfa-kæde-nukleinsyremolekyler, korresponderende proteiner og anvendelse heraf
PL400309A1 (pl) Kwasy nukleinowe, proteiny oraz przeciwciala BTL-II
WO2002014369A3 (en) Human kininogen d5 domain polypeptides and their use
WO2006042005A3 (en) Global gene expression profiling of circulating tumor cells

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE 5A,, 6A. E 7A. ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2064 DE 27/07/2010.

B15K Others concerning applications: alteration of classification

Ipc: C07K 16/28 (2006.01), A61K 39/00 (2006.01)